Phase II Trial of Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma
This study tests a combination of two medications, a pill called tipifarnib and an antibody therapy called naxitamab, for children and young adults with neuroblastoma. The goal is to see how safe this combination is and how well it helps fight cancer that has returned or did not fully go away with past treatments.
This study is for patients older than 12 months and up to 21 years old at their original diagnosis who have a confirmed diagnosis of neuroblastoma. Participants must have cancer that came back or did not fully respond to standard treatments, and they cannot be on any other experimental drugs right now.
Participants will take the tipifarnib pill by mouth and receive naxitamab through an intravenous line, which is a liquid delivered directly into a vein. Doctors will closely monitor safety, side effects, and how well the treatment shrinks the cancer or stops it from growing.
This study is currently recruiting participants at multiple hospital locations across the United States, including cities in Arkansas, Connecticut, and Florida. You can talk to your care team to see if one of these locations is right for you.
- 1Tests a combination of a targeted oral pill and an immune system antibody.
- 2Designed for children and young adults with neuroblastoma that returned or resisted past treatments.
- 3Currently recruiting patients at select medical centers in the United States.
Related links
Outside pages about this study, checked by our team
This summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.